188 results on '"ALLEGRO R"'
Search Results
2. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study
3. The feasibility and prognostic value of sequential evaluation of EGFR cell expression in bladder washings after transurethral resection of Non-Muscle Invasive Bladder Cancer: A new potential tool to identify patients at higher risk of disease progression
4. EGFR cell expression during adjuvant treatment after transurethral resection for non-muscle invasive bladder cancer
5. SC70 - The feasibility and prognostic value of sequential evaluation of EGFR cell expression in bladder washings after transurethral resection of Non-Muscle Invasive Bladder Cancer: A new potential tool to identify patients at higher risk of disease progression
6. 1083 - EGFR cell expression during adjuvant treatment after transurethral resection for non-muscle invasive bladder cancer
7. Serenoa repens, lycopene and selenium vs tamsulosin in the treatment of LUTS/BPH: An Italian multicenter randomized comparative study between single or combination therapies (Procomb Study)
8. SERENOA REPENS, LICOPENE E SELENIUM VS. TAMSULOSINA PER IL TRATTAMENTO DEI LUTS: UNO STUDIO ITALIANO MULTICENTRICO RANDOMIZZATO COMPARATIVO TRA LA MONOTERAPIA O LA COMBINAZIONE (PROCOMB STUDY)
9. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB Trial)
10. RISULTATI DI UNO STUDIO RANDOMIZZATO SULLA TOSSICITÀ E SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR DI CARCINOMA VESCICALE SUPERFICIALE
11. Living Conditions in the Historical Center of Palermo
12. Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale
13. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma
14. Smoking Status, Recurrence Risk and Intravesical Chemotherapy In Non-muscle-invasive Bladder Cancer
15. LUTS e DE nella pratica clinica andrologica in Sicilia : analisi epidemiologica su condizioni di familiarità (patologie uro-genitali), comorbidità, alterazioni all’esame obiettivo
16. Members of the foundation Gruppo Studi Tumori Urologici (GSTU). Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma
17. Prostatite cronica sintomatica nella pratica clinica uro-andrologica in Sicilia : profilo clinico, diagnosi e trattamento
18. Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder
19. Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder - A study from Gruppo Studi Tumori Urologici (GSTU) Foundation
20. Valutazione della terapia a lungo termine con Tadalafil in pazienti con disfunzione erettile: update dopo 6 mesi
21. Valutazione della terapia a lungo termine con Tadalafil in differenti classi di pazienti con disfunzione erettile
22. FUMO DI SIGARETTA E RISORSA IDRICA IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE SUPERFICIALE
23. CHEMIOTERAPIA DOMICILIARE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO DI FASE II DEL GRUPPO STUDIO TUMORI UROLOGICI (GSTU)
24. Reduction to Commercial Practice
25. 774 Serenoa repens, lycopene and selenium vs tamsulosin in the treatment of LUTS/BPH: An Italian multicenter randomized comparative study between single or combination therapies (Procomb Study)
26. 1040 Smoking status at diagnosis and outcome of intermediate-risk non muscle-invasive bladder carcinoma (NMI-BC) treated by TUR and adjuvant intravesical chemotherapy
27. 432 RE-TREATMENT BY INTRAVESICAL THERAPY IN RECURRING PATIENTS AFFECTED BY INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC)
28. 1041 MONTHLY MAINTENANCE AFTER EARLY INTRAVESICAL CHEMOTHERAPY
29. 49 POSITIVE NMP22 AND ABSENCE OF EVIDENT UROLOGICAL DISEASE IN PATIENTS FOLLOWED FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC). LONG TERM OUTCOME
30. 191 CAN SINGLE DOSE PRULIFLOXACIN IMPROVE PATIENTS' COMPLIANCE TO BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPY?
31. Results at 48 Months of a Randomized Trial on Maintenance after Early Adjuvant
32. Conservative Management and Survival of Patients Affected by T1G3 Bladder Tumours. When Shall we Indicate it and When the Cystectomy?
33. Low-Risk Bladder Tumors: How Accurate are the EORTC Risk Tables?
34. A RANDOMISED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER
35. MANAGEMENT OF BICALUTAMIDE INDUCED GYNAECOMASTIA. A RANDOMISED STUDY COMPARING THERAPY VERSUS PROPHYLAXIS WITH TAMOXIFEN
36. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients
37. Analysis of serum HER-2/neu levels (S-HER2) in breast cancer (BC) patients (pts)
38. Preliminary Report of a Multicentric Study on Environmental Risk Factors in Ta-T1 Transitional Cell Carcinoma of the Bladder
39. Variations PSA Value in Patients Candidate to Biopsy of the Prostate
40. Prediction by quantitative histology of pathological stage in prostate cancer
41. 871Water chlorination and other environmental factors in bladder cancer. Result of a multicentre study
42. The Prognostic Value of P53 in Predicting of Bladder Carcinoma
43. 827 Environmental factors in superficial bladder cancer. Preliminary report of a prospective study
44. Risk factor analysis in 165 selected patients with T1G3 transitional cell carcinoma of the bladder treated by TUR plus adjuvant intravesical therapy
45. Trattamento conservativo e sopravvivenza in pazienti affetti da urotelioma vescicale T1G3. Quando proporlo e quando la cistectomia?
46. Risultati a 48 mesi di uno studio randomizzato sull'efficacia del mantenimento dopo chemioterapia endovescicale con inizio precoce in pazienti affetti da uroteliomi a rischio intermedio.
47. Osservational Study on Early Diagnosis of Prostate Carcinoma in Sicily and Calabria
48. Environmental Risk Factors in Superficial Bladder Cancer
49. Uroteliomi vescicali a basso rischio: quanto affidabili sono le EORTC Risk Tables?
50. ROLE OF ANTIMICROBIAL TREATMENT IN PATIENTS WITH ELEVATED PSA AND NORMAL DIGITAL RECTAL EXAMINATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.